

Variant: NM_001126112.2(TP53):c.998G>A (p.Arg333His)

Version: 2.0

CA000533 [↗](#)

142273 (ClinVar) [↗](#)

Gene: TP53 ([HGNC:7157](#))

Condition: Li-Fraumeni syndrome ([MONDO:0018875](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: d8de06fc-22f0-4978-9c21-a8d7b365d2c9

Approved on: 2025-03-04

Published on: 2025-06-23

HGVS expressions

NM_001126112.2:c.998G>A

NM_001126112.2(TP53):c.998G>A (p.Arg333His)

NC_000017.11:g.7670711C>T

CM000679.2:g.7670711C>T

NC_000017.10:g.7574029C>T

CM000679.1:g.7574029C>T

NC_000017.9:g.7514754C>T

NG_017013.2:g.21840G>A

ENST00000503591.2:c.998G>A

ENST00000508793.6:c.998G>A

ENST00000509690.6:c.602G>A

ENST00000514944.6:c.719G>A

ENST00000604348.6:c.977G>A

ENST00000269305.9:c.998G>A

ENST00000269305.8:c.998G>A

ENST00000359597.8:c.993+2824G>A

ENST00000413465.6:c.782+3470G>A

ENST00000420246.6:c.*105G>A

ENST00000445888.6:c.998G>A

ENST00000455263.6:c.*17G>A

ENST00000504290.5:c.*17G>A

ENST00000504937.5:c.602G>A

ENST00000510385.5:c.*105G>A

ENST00000576024.1:c.54-1021G>A

ENST00000610292.4:c.881G>A

ENST00000610538.4:c.*17G>A

ENST00000610623.4:c.*17G>A

ENST00000615910.4:c.965G>A

ENST00000617185.4:c.*105G>A

ENST00000618944.4:c.*105G>A

ENST00000619186.4:c.521G>A

ENST00000619485.4:c.881G>A

ENST00000620739.4:c.881G>A

ENST00000622645.4:c.*105G>A

ENST00000635293.1:c.881G>A

NM_000546.5:c.998G>A

NM_001126113.2:c.*17G>A

NM_001126114.2:c.*105G>A
NM_001126115.1:c.602G>A
NM_001126116.1:c.*105G>A
NM_001126117.1:c.*17G>A
NM_001126118.1:c.881G>A
NM_001276695.1:c.*17G>A
NM_001276696.1:c.*105G>A
NM_001276697.1:c.521G>A
NM_001276698.1:c.*105G>A
NM_001276699.1:c.*17G>A
NM_001276760.1:c.881G>A
NM_001276761.1:c.881G>A
NM_001276695.2:c.*17G>A
NM_001276696.2:c.*105G>A
NM_001276697.2:c.521G>A
NM_001276698.2:c.*105G>A
NM_001276699.2:c.*17G>A
NM_001276760.2:c.881G>A
NM_001276761.2:c.881G>A
NM_000546.6:c.998G>A
NM_001126112.3:c.998G>A
NM_001126113.3:c.*17G>A
NM_001126114.3:c.*105G>A
NM_001126115.2:c.602G>A
NM_001126116.2:c.*105G>A
NM_001126117.2:c.*17G>A
NM_001126118.2:c.881G>A
NM_001276695.3:c.*17G>A
NM_001276696.3:c.*105G>A
NM_001276697.3:c.521G>A
NM_001276698.3:c.*105G>A
NM_001276699.3:c.*17G>A
NM_001276760.3:c.881G>A
NM_001276761.3:c.881G>A

Benign

Met criteria codes **3**

BP4 BS3 BS2

Not Met criteria codes **12**

BS1 BS4 PP1 PP3 PS1 PS2
PS3 PS4 BA1 PM1 PM5
PM2

Evidence Links **0**

Expert Panel

TP53 VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** *ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0*

[↗](#) **Criteria Specification Approval History**







[↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel













TP53 VCEP












The NM_000546.6: c.998G>A variant in TP53 is a missense variant predicted to cause substitution of arginine by histidine at amino acid 333 (p.Arg333His). This variant has been observed in 4-7 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Moderate; ClinVar SCVs: SCV000285219.10). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 29979965, 30224644). Computational predictor scores (BayesDel = -0.0924; Align GVGD Class C0) are below the recommended thresholds (BayesDel \leq -0.008 and an Align GVGD Class \leq 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4_Moderate). In summary, this variant meets the criteria to be classified as benign for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2_Moderate, BS3, BP4_Moderate. (Bayesian Points: -8; VCEP specifications version 2.3; 3/4/2025).

Met criteria codes

BP4	 	MODERATE. Computational predictor scores (BayesDel = -0.0924; Align GVGD Class C0) are below the recommended thresholds (BayesDel \leq -0.008 and an Align GVGD Class \leq 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing. (BP4_Moderate).
BS3	 	In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function(BS3; PMIDs: 12826609, 29979965, 30224644).
BS2	 	MODERATE. This variant has been observed in 4-7 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Moderate; ClinVar SCVs: SCV000285219.10).

Not Met criteria codes

BS1	 	The highest population minor allele frequency in gnomAD v4.1.0 is 0.00008789 (8/91026 alleles) in the South Asian population (PM2, BS1, and BA1 are not met).
BS4	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP1	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

PS3			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1			The highest population minor allele frequency in gnomAD v4.1.0 is 0.00008789 (8/91026 alleles) in the South Asian population (PM2, BS1, and BA1 are not met).
PM1			This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met).
PM5			Another missense variant (c.997C>T, p.Arg333Cys) in the same codon has been reported (ClinVar Variation ID: 184745). However, the variants have not yet been curated to determine if they would be classified as pathogenic or likely pathogenic by the ClinGen TP53 VCEP's specifications (PM5 not evaluated).
PM2			The highest population minor allele frequency in gnomAD v4.1.0 is 0.00008789 (8/91026 alleles) in the South Asian population (PM2, BS1, and BA1 are not met).

Curation History [↗](#)

Showing 1 to 2 of 2 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.